Moclobemide Sandoz (Moclobemide)

Moclobemide selectively blocks the enzyme monoamine oxidase A (MAO‑A). This inhibition reduces the breakdown of serotonin, norepinephrine and dopamine, resulting in higher concentrations of these mood‑regulating neurotransmitters and an improvement in depressive symptoms.

The dosage of Moclobemide Sandoz is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength, frequency and duration of therapy.

The pregnancy category for moclobemide is not definitively established. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant, and after a careful risk‑benefit assessment by the healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moclobemide differs from traditional irreversible MAO inhibitors by being reversible and selective for MAO‑A, which generally results in a more favorable dietary restriction profile. Compared with SSRIs or SNRIs, it may be chosen when patients have contraindications to those classes or require a different mechanism of action.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture, light and excessive heat. Do not store in the bathroom or near a kitchen sink where humidity is high.

Moclobemide Sandoz is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious adverse events include hypertensive crisis when tyramine‑rich foods are consumed, serotonin syndrome when combined with other serotonergic agents, and severe liver injury. Patients should be educated about dietary restrictions and promptly report any signs of severe headache, chest pain, rapid heart rate or jaundice.

Moclobemide is contraindicated in patients with known hypersensitivity to the drug, those taking other MAO inhibitors, and individuals with pheochromocytoma or severe liver disease. Caution is also advised for patients on serotonergic medications, certain opioids, or those with uncontrolled hypertension.